IITZ-01
Modify Date: 2023-01-18 15:55:16
IITZ-01 structure
|
Common Name | IITZ-01 | ||
|---|---|---|---|---|
| CAS Number | 1807988-47-1 | Molecular Weight | 482.51 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C26H23FN8O | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of IITZ-01IITZ-01 is a potent lysosomotropic autophagy inhibitor with single-agent antitumor activity, with an IC50 of 2.62 μM for PI3Kγ. |
| Name | IITZ-01 |
|---|
| Description | IITZ-01 is a potent lysosomotropic autophagy inhibitor with single-agent antitumor activity, with an IC50 of 2.62 μM for PI3Kγ. |
|---|---|
| Related Catalog | |
| Target |
PI3Kγ:2.62 μM (IC50) Autophagy |
| In Vitro | IITZ-01 shows negligible inhibition toward PI3Kγ (IC50: 2.62μM). Time-course immunoblotting experiment with IITZ-01-treated cells also displays significant elevation in SQSTM1 levels, indicating the autophagy inhibitory nature of the compound. In addition to that, both compounds IITZ-01 has demonstrated potent autophagy inhibitory activity in other breast, lung, and colon cancer cells[1]. |
| In Vivo | Tumors after reaching ~100 mm3, vehicle, 45 mg/kg of IITZ-01, is administered through intraperitoneal (i.p.) route on every alternate day for 4 weeks. IITZ-01 reduces the active tumor burden around 8.8-fold, when compared with control group as determined by tumor photon counts. Moreover, tumor volume measurements have demonstrated that IITZ-01 has significantly inhibited average tumor growth when compared with control from third day of treatment. Significant reduction in average tumor weights is observed after treatment with IITZ-01 compared with control. This treatment schedule of both compounds is well tolerated in mice for the total duration of administration with no significant changes in their body weights[1]. |
| References |
| Molecular Formula | C26H23FN8O |
|---|---|
| Molecular Weight | 482.51 |
| Storage condition | 2-8℃ |